Выраженность кислотосупрессивного действия ингибиторов протонной помпы и эффективность современных эрадикационных схем


Ю.А. Кучерявый, Е.В. Баркалова

Во многих странах Запада, Японии и Австралии отмечена тенденция к уменьшению заболеваемости язвенной болезнью и некардиальным раком желудка, прямо коррелирующая со снижением распространенности инфекции Helicobacter pylori в популяции. Почти 3 десятилетия практического применения антихеликобактерной терапии, сотни проведенных клинических исследований и более 100 мета-анализов контролируемых исследований однозначно свидетельствуют об отсутствии гарантированного успеха вне зависимости от выбранной схемы лечения. В данной статье рассмотрены факты значимости антисекретороной терапии в эрадикационных схемах, обсуждаются перспективы повышения эффективности лечения инфекции H. pylori за счет увеличения доз ингибиторов протонной помпы.

Литература


1. Дехнич Н.Н., Костякова Е.А., Пунин А.А. и др. Антибиотикорезистентность H.pylori: результаты микробиологического регио-нального исследования // Росс. журн. гастроэнтерол., гепатол., колопроктол. 2011. No 2. С. 37–42.


2. Ивашкин В.Т., Маев И.В., Лапина Т.Л. и др. Рекомендации Российской гастроэнтерологи- ческой ассоциации по лечению инфекции H. pylori у взрослых // Росс. журн. гастроэнтерол., гепатол., колопроктол. 2012. No 1. С. 87–89.


3. Кучерявый Ю.А., Баркалова Е.В. Двойные дозы ингибиторов протонной помпы – путь повышения эффективности тройной антихеликобактерной терапии первой линии // Лечебное дело 2012. No 1. С. 36–42.


4. Саблин О.А. Проблема резистентности Helicobacter pylori к кларитромицину // Consilium Medicum. Гастроэнтерология 2011. No 2. С. 34–38.


5. Abuzarova ER, et al. Synopsis 2011 XXIVth International Workshop on Helicobacter and relat- ed bacteria in chronic digestive inflammation and gastric cancer. September 11–13, 2011 Dublin, Ireland.


6. Anagnostopoulos GK, Tsiakos S, Margantinis G, et al. Esomeprazole versus omeprazole for the eradi- cation of Helicobacter pylori infection: results of a randomized controlled study. J Clin Gastroenterol 2004;38(6):503–6.


7. Basso D, Plebani M, Kusters JG. Pathogenesis of Helicobacter pylori infection. Helicobacter. 2010;15(Suppl. 1):14–20.


8. Buzás G.M. First-line eradication of Helicobacter pylori: are the standard triple therapies obsolete? A different perspective. World J Gastroenterol 2010;16(31):3865–70.


9. Calabresi L, Pazzucconi F, Ferrara S, et al. Pharmacokinetic interactions between omepraz- ole/pantoprazole and clarithromycin in health volunteers. Pharmacol Res 2004;49(5):493–99.


10. Chang CS, Yang CY, Wong FN, et al. The effect of intragastric acidity on Helicobacter pylori eradication with bismuth-metronidazole-amox- icillin. Hepatogastroenterology 1999;46(28): 2713–17.


11. Chey WD, Wong BC. American College of Gastroenterology guideline on the management of Helicobacter pylori infection. Am J Gastroenterol 2007;102:1808–25.


12. Choi HS, Park DI, Hwang SJ, et al. Double-dose, new-generation proton pump inhibitors do not improve Helicobacter pylori eradication rate. Helicobacter 2007;12:638–42.


13. Erah PO, Goddard AF, Barrett DA, et al. The sta- bility of amoxycillin, clarithromycin and metro- nidazole in gastric juice: relevance to the treatment of Helicobacter pylori infection. J Antimicrob Chemother 1997;39(1):5–12.


14. Fischbach LA, Goodman KJ, Feldman M, et al. Sources of variation of Helicobacter pylori treat- ment success in adults worldwide: a meta-analysis. Int J. Epidemiol 2002;31:128–39.


15. Fuccio L, Minardi ME, Zagari RM, et al. Meta- analysis: duration of first-line proton-pump inhibi- tor based triple therapy for Helicobacter pylori erad- ication. Ann Intern Med 2007;147(8):553–62.


16. Gisbert JP, Dominguez-Munoz A, Dominguez- Martin A, et al. Esomeprazole-based therapy in Helicobacter pylori eradication: any effect by increasing the dose of esomeprazole or pro- longing the treatment? Am J Gastroenterol 2005;100:1935–40.


17. Graham DY, Shiotani A. New concepts of resis- tance in the treatment of Helicobacter pylori infections. Nat Clin Pract Gastroenterol Hepatol 2008;5(6):321–31.


18. Graham DY, Fischbach L. Helicobacter pylori treat- ment in the era of increasing antibiotic resistance. Gut 2010;59(8):1143–53.


19. Hsu PI, Lai KH, Wu CJ, et al. High-dose versus low-dose esomeprazole-based triple therapy for Helicobacter pylori infection. Eur J Clin Invest 2007;37:724–30.


20. http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/ Guidances/UCM184500.pdf


21. Lazebnik LB, et al. Synopsis 2011 XXIVth International Workshop on Helicobacter and relat- ed bacteria in chronic digestive inflammation and gastric cancer. September 11–13, 2011 Dublin, Ireland.


22. Malfertheiner P, Megraud F, O’Morain C, et al. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut 2007;56(6):772–81.


23. Malfertheiner P, Selgrad M. Helicobacter pylori infection and current clinical areas of contention. Curr Opin Gastroenterol 2010;26(6):618–23.


24. Malfertheiner P, Megraud F, O’Morain CA, et al.; European Helicobacter Study Group. Management of Helicobacter pylori infection – the Maastricht IV/ Florence Consensus Report. Gut 2012; 61(5):646–64.


25. Manes G, Pieramico O’ Perri F, et al. Twice daily standard dose of omeprazole achieves the neces- sary level of acid inhibition for Helicobacter pylori eradication. A randomized controlled trial using standard and double doses of omeprazole in triple therapy. Dig Dis Sci 2005;50:443–44.


26. McNicholl AG, Linares PM, Nyssen OP, et al. Meta- analysis: esomeprazole or rabeprazole vs. first- generation pump inhibitors in the treatment of Helicobacter pylori infection. Aliment Pharmacol Ther 2012;36(5):414–25.


27. Nakajima S, Nishiyama Y, Yamaoka M, et al. Changes in the prevalence of Helicobacter pylori infection and gastrointestinal diseases in the past 17 years. J Gastroenterol Hepatol 2010;25(Suppl. 1):S99–S110.


28. O’Connor A, Gisbert JP, McNamara D, O’Morain C. Treatment of Helicobacter pylori infection 2010. Helicobacter 2010;15(Suppl. 1):46–52.


29. Scott D, Weeks D, Melchers K, et al. The life and death of Helicobacter pylori. Gut 1998;43(Suppl. 1):S56–S60.


30. Sheu BS, Kao AW, Cheng HC, et al. Esomeprazole 40 mg twice daily in triple therapy and the effi- cacy of Helicobacter pylori eradication related to CYP2C19 metabolism. Aliment Pharmacol Ther 2005;21(3):283–88.


31. Sugimoto M, Furuta T, Shirai N, et al. Evidence that the degree and duration of acid suppression are related to Helicobacter pylori eradication by triple therapy. Helicobacter 2007;12(4):317–23.


32. Sun Q, Liang X, Zheng Q, et al. High efficacy of 14-day triple therapy-based, bismuth-containing quadruple therapy for initial Helicobacter pylori eradication. Helicobacter 2010;15(3):233–38.


33. Tan VP, Wong BC. Helicobacter pylori and gastritis: Untangling a complex relationship 27 years on. J Gastroenterol Hepatol 2011;26 (Suppl. 1):42–5.


34. Taylor DE. Pathophysiology of antibiotic resis- tance: clarithromycin. Can J Gastroenterol 2000;14(10):891–94.


35. Vallve M, Vergara M, Gisbert JP, Calvet X. Single vs. double dose of a proton pump inhibitor in triple therapy for Helicobacter pylori eradica- tion: a meta-analysis. Aliment Pharmacol Ther 2002;16(6):1149–56.


36. Villoria A, Garcia P, Calvet X, et al. Meta-analysis: high-dose proton pump inhibitors vs. standard dose in triple therapy for Helicobacter pylori eradication. Aliment Pharmacol Ther 2008;28(7):868–77.


37. Wang AY, Peura DA. The prevalence and incidence of Helicobacter pylori-associated peptic ulcer dis- ease and upper gastrointestinal bleeding through- out the world. Gastrointest Endosc Clin N Am 2011;21(4):613–35.


38. Xia HH, Phung N, Altiparmak E, et al. Reduction of peptic ulcer disease and Helicobacter pylori infec- tion but increase of reflux esophagitis in Western Sydney between 1990 and 1998. Dig Dis Sci 2001;46(12):2716–23.


39. Yoon JH, Baik GH, Kim YS, et al. Comparison of the Eradication Rate between 1- and 2-Week Bismuth-Containing Quadruple Rescue Therapies for Helicobacter pylori Eradication. Gut Liver 2012;6(4):434–39.


Похожие статьи


Бионика Медиа